J Clin Neurol. 2019 Oct;15(4):488-495
The present study, for the first time, provides the evidence that combined assessment of serum alpha-synuclein and Rab35 is the predictive biomarker for sporadic PD patients with a younger age.
Summary
It is essential to develop a reliable predictive serum biomarker of Parkinson’s disease (PD).
Accumulation of α-synuclein (αSyn) and upregulated expression of Rab35 participate in the etiology of PD. The purpose of this investigation was to explore whether combined analysis of serum αSyn and Rab35 is a predictive biomarker of PD.
Methods:
Serum levels of αSyn or Rab35 were determined in serum samples from 59 sporadic PD patients, 19 progressive supranuclear palsy (PSP) patients, 20 multiple system atrophy (MSA) patients or 60 normal controls (NC). Receiver operating characteristic curves were obtained to determine diagnostic accuracy of αSyn or/and Rab35 in discriminating PD patients from NC or atypical parkinsonian patients.
Results:
Levels of αSyn and Rab35 were increased in PD patients. Levels of serum Rab35 were positively correlated with concentrations of serum αSyn in PD patients. Compared to analyzing αSyn or Rab35 alone, combined analysis of αSyn and Rab35 had a higher value of the area under ROC curve (AUC) and a better performance in discriminating PD patients from NC, MSA or PSP patients. When splitting age was 55-, 60-, 65- or 70-years old, combined analysis of αSyn and Rab35 for classifying PD in the group of below cut-off age had a better predictive performance than in the group of above cut-off age.
Conclusions:
Combined assessment of serum αSyn and Rab35 is a better biomarker for discriminating PD patients from NC or atypical parkinsonian patients, and is a predictive biomarker of sporadic PD patients with younger age.
Comments